|本期目录/Table of Contents|

[1]杨 洁,魏 芳,王立华,等.不同血清钙水平对终末期肾脏病患者血管钙化及心血管原因死亡的影响[J].天津医科大学学报,2017,23(04):320-323.
　YANG Jie,WEI Fang,WANG Li-hua,et al.Correlation between serum calcium and the vascular calcification and cardiovascular mortality in patients with end-stage renal disease[J].Journal of Tianjin Medical University,2017,23(04):320-323.
点击复制

不同血清钙水平对终末期肾脏病患者血管钙化及心血管原因死亡的影响(PDF)
分享到：

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
23卷
期数:
2017年04期
页码:
320-323
栏目:
临床医学
出版日期:
2017-07-02

文章信息/Info

Title:
Correlation between serum calcium and the vascular calcification and cardiovascular mortality in patients with end-stage renal disease
文章编号:
1006-8147(2017)04-0320-04
作者:
杨 洁; 魏 芳; 王立华; 于海波; 卢 志; 王喆; 姜埃利
（天津医科大学第二医院血液净化治疗中心，天津 300211）
Author(s):
YANG Jie;  WEI Fang; WANG Li-hua; YU Hai-bo;  LU Zhi; WANG Zhe;  JIANG Ai-li
（Blood Purification Division of Nephrology, The Second Hospital , Tianjin Medical University, Tianjin 300211, China）
关键词:
血清钙水平; 血管钙化; 终末期肾脏病; 死亡率
Keywords:
serum calcium ;  vascular calcification ;  end-stage renal disease ;  mortality
分类号:
-
DOI:
-
文献标志码:
A
摘要:
目的 :研究不同血清钙水平对终末期肾脏病维持性血液透析患者血管钙化及心血管原因死亡的影响。方法:选取行规律血液透析治疗的终末期肾脏病患者160例，根据血钙水平将入选患者分为3组：低血清钙组（2.0 mmol/L＜Ca＜2.25 mmol/L）、正常血清钙组（2.25 mmol/L≤Ca≤2.75 mmol/L）、高血清钙组（Ca＞2.75 mmol/L）。采用X线摄片评价血管钙化的情况，并记录患者临床资料。随访24个月，观察24个月内三组患者发生心血管事件的情况，记录患者因心血管原因死亡的发生时间。Kaplan-Meier生存分析法计算患者生存率。结果:最终有147例患者完成研究，年龄（57.76±13.43）岁，男性72例（48.9%）。患者血管钙化程度与血清钙水平呈正相关。3组患者发生心血管事件的差异有统计学意义（P＜0.05）。Kaplan-Meier生存分析法显示：3组患者在心血管原因死亡率（P=0.012）上差异有统计学意义，血钙水平越高，生存率越低。结论:血清钙水平在一定程度上可影响终末期肾脏病维持性血液透析患者血管钙化及心血管原因死亡率。
Abstract:
Objective: To investigate the correlation between serum calcium and the vascular calcification and cardiovascular mortality in patients with end-stage renal disease (ESRD). Methods: Clinical data of 160 cases of ESRD patients with regular hemodialysis were included. All cases were divided into three groups based on the serum calcium level: lower than normal (2.0 mmol/L＜Ca＜2.25 mmol/L), normal(2.25 mmol/L≤Ca≤2.75 mmol/L), higher than normal (Ca ＞2.75 mmol/L). All the clinical data including age, gender, serum calcium, vascular calcification rate and cardiac event occurrence rate were recorded. The vascular calcification was measured using X-rays. And the cardiac event occurrence rates in two years of all cases with different serum calcium levels were recorded. Kaplan-Meier methods were used to compute the survival rate. Results: There were 147 patients enrolled in the study at last, with a mean age of (57.76±13.43) years old, and 72 of them were male (48.9%). The degree of vascular calcification and serum calcium levels were positively correlated. The occurrences of cardiovascular event for the three groups had significance differences (P＜0.05）. The cardiovascular mortalities in 24 months for the three groups had significance differences（P=0.012）. Conclusion: The level of serum calcium may influence the vascular calcification and cardiovascular mortality in end-stage renal disease patients to some degree.

参考文献/References:

[1] Parfrey P S, Foley R N. The clinical epidemiology of cardiac disease in chronic renal failure[J]. J Am Soc Nephrol, 1999,10(7):1606

[2] Goodman W G, Goldin J, Kuizon B D, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis[J]. N Engl J Med, 2000,342(20):1478

[3] Raggi P, Boulay A, Chasan-Taber S, et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular diseaseJ]. J Am Coll Cardiol, 2002,39(4):695

[4] Adragao T, Pires A, Lucas C, et al. A simple vascular calcification score predicts cardiovascular risk in haemodialysis patients[J]. Nephrol Dial Transplant, 2004,19(6):1480

[5] O’Neill W C. Targeting serum calcium in chronic kidney disease and end-stage renal disease: is normal too high[J]. Kidney Int, 2016. 89(1): 40

[6] Sigrist M, Bungay P, Taal M W, et al. Vascular calcification and cardiovascular function in chronic kidney disease[J]. Nephrol Dial Transplant, 2006,21(3):707

[7] Jean G, Bresson E, Terrat J C, et al. Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences[J]. Nephrol Dial Transplant, 2009,24(3):948

[8] Karohl C, D’Marco G L, Raggi P. Noninvasive imaging for assessment of calcification in chronic kidney disease[J]. Nat Rev Nephrol, 2011,7(10):567

[9] Byon C H, Chen Y. Molecular Mechanisms of Vascular Calcification in Chronic Kidney Disease: The Link between Bone and the Vasculature[J]. Curr Osteoporos Rep, 2015,13(4):206.

[10] Palit S, Kendrick J. Vascular calcification in chronic kidney disease: role of disordered mineral metabolism[J]. Curr Pharm Des, 2014,20(37):5829.

[11] Neven E, De Schutter TM, De Broe ME, et al. Cell biological and physicochemical aspects of arterial calcification[J]. Kidney Int, 2011,79(11):1166.

[12] Demer LL, Tintut Y. Vascular calcification: pathobiology of a multifaceted disease[J]. Circulation, 2008,117(22):2938.

[13] Jean G, Mayor B, Deleaval P, et al. Vascular calcification progression is an independent predictor of mortality in patients on haemodialysis[J]. Nephron, 2015,130(3):169

[14] Moldovan D, Rusu C, Kacso I M, et al. Mineral and bone disorders, morbidity and mortality in end-stage renal failure patients on chronic dialysis[J]. Clujul Med, 2016,89(1):94

[15] Young E W, Albert J M, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study[J]. Kidney Int, 2005,67(3):1179

[16] Block G A, Klassen P S, Lazarus J M, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis[J]. J Am Soc Nephrol, 2004,15(8):2208

[17] Maeda S, Sutliff R L, Qian J, et al. Targeted overexpression of parathyroid hormone-related protein (PTHrP) to vascular smooth muscle in transgenic mice lowers blood pressure and alters vascular contractility[J]. Endocrinology, 1999,140(4):1815

[18] Luo X H, Liao E Y, Su X, et al. Parathyroid hormone inhibits the expression of membrane-type matrix metalloproteinase-1 (MT1-MMP) in osteoblast-like MG-63 cells[J]. J Bone Miner Metab, 2004,22(1):19

[19] Cheng S L, Shao J S, Halstead L R, et al. Activation of vascular smooth muscle parathyroid hormone receptor inhibits Wnt/beta-catenin signaling and aortic fibrosis in diabetic arteriosclerosis[J]. Circ Res, 2010,107(2):271

[20] Rashid G, Bernheim J, Green J, et al. Parathyroid hormone stimulates endothelial expression of atherosclerotic parameters through protein kinase pathways[J]. Am J Physiol Renal Physiol, 2007,292(4):F1215

[21] Felsenfeld A J, Rodriguez M, Aguilera-Tejero E. Dynamics of parathyroid hormone secretion in health and secondary hyperparathyroidism[J]. Clin J Am Soc Nephrol, 2007,2(6):1283

相似文献/References:

备注/Memo

备注/Memo:
基金项目天津医科大学科研基金（2015KYZQ15）

作者简介 杨洁（1989-），女，硕士在读，研究方向：血液净化；

通信作者：姜埃利， E-mail： carlos_j@126.com。



更新日期/Last Update: 2017-07-01